)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Tempest Therapeutics (TPST) investor relations material
Tempest Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary11 Aug, 2025
Executive summary
Clinical-stage biotech focused on cancer therapies, with amezalpat ready for pivotal Phase 3 in liver cancer and TPST-1495 entering Phase 2 for FAP, both with recent regulatory designations and positive trial data.
Cleared to begin pivotal amezalpat trial for first-line HCC in China, expanding on prior US and EU clearances.
Received orphan drug designations for amezalpat (HCC) and TPST-1495 (FAP) from FDA and EMA.
In April 2025, initiated a strategic review to explore alternatives including mergers, acquisitions, or partnerships, and implemented significant cost reductions including a 21-person workforce reduction.
Key executives transitioned to consulting roles; company retained MTS Health Partners to advise on strategic options.
Financial highlights
Cash and cash equivalents were $14.3 million as of June 30, 2025, down from $30.3 million at December 31, 2024.
Net loss for Q2 2025 was $7.9 million ($2.07/share), a decrease from $9.6 million ($5.52/share) in Q2 2024; net loss for the six months ended June 30, 2025 was $18.7 million ($5.17/share), up from $17.5 million ($10.15/share) year-over-year.
Research and development expenses for Q2 2025 were $3.9 million, down 34% year-over-year; general and administrative expenses increased to $4.1 million, mainly due to one-time separation costs.
Operating cash outflows for the first half of 2025 were $16.5 million, compared to $12.7 million in the prior year period.
Raised $4.1 million in a registered direct offering and $2.8 million via ATM program in H1 2025; repaid $3.5 million to fully satisfy outstanding loan.
Outlook and guidance
Existing cash is expected to fund operations for less than 12 months from the date of the financial statements, raising substantial doubt about going concern.
Advancement of amezalpat into Phase 3 and TPST-1495 into Phase 2 is contingent on securing additional resources or a strategic transaction.
Actively pursuing strategic alternatives to advance clinical programs and maximize stockholder value.
Ongoing strategic review may result in mergers, acquisitions, partnerships, or other transactions; no timetable set for completion.
Update on strategic alternatives process
Pivotal trial funding strategy?
Cash runway projection?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Tempest Therapeutics earnings date
Q3 202511 Nov, 2025
Next Tempest Therapeutics earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Tempest Therapeutics Inc. is a clinical-stage biotechnology firm dedicated to developing small molecule therapeutics aimed at treating cancer. Their approach involves mechanisms that not only directly kill tumor cells but also activate tumor-specific immunity. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage